Methods of treating Syndrome X with aliphatic polyamines

Details Methods of treating Syndrome X with aliphatic polyamines Methods of treating Syndrome X with aliphatic polyamines

2007-08-28

2007-08-28

Hartley, Michael G. (Department: 1618)

Drug, bio-affecting and body treating compositions

Solid synthetic organic polymer as designated organic active...

Polymer from ethylenic monomers only

C424S078350

Reexamination Certificate

active

10125701

ABSTRACT:
The invention relates to a method for treating Syndrome X, or inhibiting the onset of symptoms of Syndrome X in a patient, and includes administering a therapeutically effective amount of a salt of at least one alkylated and cross-linked polymer, or a copolymer thereof, the polymer salt formed as a product of the reaction of one or more polymers, or salts and copolymers thereof, having a repeat unit that is essentially:where n is a positive integer and each R, independently, is H or a C1–C8alkyl group; at least one aliphatic alkylating agent; and a cross-linking agent. Long term administration of the cross-linked polyamine salts of the invention increases HDL levels and decreases LDL levels in patients. The invention also provides for administration of the polymer salt colesevelam, in combination with an HMG-CoA reductase inhibitor; the combined administration is effective in further lowering serum total-cholesterol and LDL-cholesterol levels beyond that achieved by either agent alone.

REFERENCES:
patent: 4231938 (1980-11-01), Monaghan et al.
patent: 4346227 (1982-08-01), Terahara et al.
patent: 4444784 (1984-04-01), Hoffman et al.
patent: 5177080 (1993-01-01), Angerbauer et al.
patent: 5273995 (1993-12-01), Roth
patent: 5354772 (1994-10-01), Kathawala
patent: 5468727 (1995-11-01), Phillips et al.
patent: 5487888 (1996-01-01), Mandeville, III et al.
patent: 5496545 (1996-03-01), Holmes-Farley et al.
patent: 5607669 (1997-03-01), Mandeville, III et al.
patent: 5618530 (1997-04-01), Mandeville, III et al.
patent: 5624963 (1997-04-01), Mandeville, III et al.
patent: 5667775 (1997-09-01), Holmes-Farley et al.
patent: 5679717 (1997-10-01), Mandeville, III et al.
patent: 5693675 (1997-12-01), Mandeville, III et al.
patent: 5702696 (1997-12-01), Mandeville, III et al.
patent: 5703188 (1997-12-01), Mandeville, III et al.
patent: 5840766 (1998-11-01), Mandeville, III et al.
patent: 5900475 (1999-05-01), Mandeville, III et al.
patent: 5917007 (1999-06-01), Mandeville, III et al.
patent: 5919832 (1999-07-01), Mandeville, III et al.
patent: 5925379 (1999-07-01), Mandeville, III et al.
patent: 5929184 (1999-07-01), Holmes-Farley et al.
patent: 5969090 (1999-10-01), Mandeville, III et al.
patent: 5981693 (1999-11-01), Mandeville, III et al.
patent: 5985935 (1999-11-01), Kharazmi et al.
patent: 6007803 (1999-12-01), Mandeville, III et al.
patent: 6034129 (2000-03-01), Mandeville, III et al.
patent: 6060517 (2000-05-01), Mandeville, III et al.
patent: 6066678 (2000-05-01), Mandeville, III et al.
patent: 6083495 (2000-07-01), Holmes-Farley et al.
patent: 6083497 (2000-07-01), Huval et al.
patent: 6129910 (2000-10-01), Holmes-Farley et al.
patent: 6177478 (2001-01-01), Holmes-Farley et al.
patent: 6190649 (2001-02-01), Holmes-Farley et al.
patent: 6203785 (2001-03-01), Holmes-Farley et al.
patent: 6225355 (2001-05-01), Mandeville, III et al.
patent: 6248318 (2001-06-01), Huval et al.
patent: 6264937 (2001-07-01), Mandeville, III et al.
patent: 6271264 (2001-08-01), Dhal et al.
patent: 6281252 (2001-08-01), Holmes-Farley et al.
patent: 6290947 (2001-09-01), Fitzpatrick et al.
patent: 6294163 (2001-09-01), Dhal et al.
patent: 6423754 (2002-07-01), Holmes-Farley et al.
patent: 6627636 (2003-09-01), Robl
patent: 2001/0044519 (2001-11-01), Mandeville, III et al.
patent: 2001/0051660 (2001-12-01), Holmes-Farley et al.
patent: 2002/0095002 (2002-07-01), Mandeville, III et al.
patent: 2002/0198202 (2002-12-01), Gwynne et al.
patent: 1 092 711 (2001-04-01), None
patent: WO84/02131 (1984-06-01), None
patent: WO92/10522 (1992-06-01), None
patent: WO94/27621 (1994-12-01), None
patent: WO95/34585 (1995-12-01), None
patent: WO95/34588 (1995-12-01), None
patent: WO96/21454 (1996-07-01), None
patent: WO96/39449 (1996-12-01), None
patent: WO 98/57652 (1998-12-01), None
patent: WO98/57652 (1998-12-01), None
patent: WO99/15186 (1999-04-01), None
patent: WO99/22744 (1999-05-01), None
patent: WO99/34787 (1999-07-01), None
patent: WO 00/38723 (2000-07-01), None
patent: WO 00/38728 (2000-07-01), None
patent: WO 00/64920 (2000-11-01), None
patent: WO 01/03705 (2001-01-01), None
patent: WO 01/25291 (2001-04-01), None
Press Release—Pharmaceutical Industry, GelTex Pharmaceuticals, Inc., May 31, 2000 “FDA Approves Welchol (Colesevelam) Lipid-Lowering Agent.”.
Chertow, G.M. et al. “Long-term effects of sevelamer hydrochloride on the calcium X phosphate product and lipid profile of haemodialysis patients,”Nephrol. Dial. Transplant.14:2907-2914 (1999).
Chertow, G.M. et al., “A randomized trial of sevelamer hydrochloride (RenaGel) with and without supplemental calcium: Strategies for the control of hyperphosphatemia in hemodialysis patients,”Clin. Nephrol.51(1):18-26 (1999).
Bleyer, A.J. et al., “A Comparison of the Calcium-Free Phosphate Binder Sevelamer Hydrochloride With Calcium Acetate in the Treatment of Hyperphosphatemia in Hemodialysis Patients,”Am. J. Kid. Dis.33(4):694-701 (1999).
Collins, A.J. et al. “Hospitalization risks between Renagel phosphate binder treated and non-Renagel treated patients,”Clin. Nephrol.54(4) :334-341 (2000).
Burke, S.K., “Renagel®: reducing serum phosphorus in haemodialysis patients,”Hospital Medicine61(9) :1-6 (Sep. 2000).
Goldberg, D.I., et al. “Effect of RenaGel®, a non-absorbed, calcium- and aluminium-free phosphate binder, on serum phosphorous, calcium, and intact parathyroid hormone in end-stage renal disease patients,”Nephrol. Dial. Transplant.13:2303-2310 (1998).
Burke, S.K. et al., “Renagel®, A Calcium and Aluminum Free Phosphate Binder Inhibits Phosphate Absorption in Normal Volunteers,” Abstract,Bone and Mineral Metabolism, A40,Nephrol. Dial. Transplant.11(6) (1996).
Burke, S.K. et al., “Renagel®, A Calcium and Aluminum Free Phosphate Binder Lowers Serum Phosphorous in Hemodialysis Patients,” Abstract,Bone and Mineral Metabolism, A41,Nephrol. Dial. Transplantat.11(6) (1996).
Slatopolsky, E. et al., “Effect of Renagel™, A Novel Phosphate Binder, on Serum Phosphorous and Parathyroid Hormone Levels in End Stage Renal Disease (ESRD) Patients,” Abstract A2859,Mineral Metabolism: Mineral-Related Hormones/Factors, J. Am. Soc. Nephrol., 7:1818 (1996).
Chertow, G.M. et al., “Poly [allylamine] hydrochloride (renagel®) [RG] with and without supplemental calcium [C] for hyperphosphatemia [HP] in ESRD,” Abstract A2559,Mineral Metabolism: Bone Disease, J. Am. Soc. Nephrol., 8:549A (1996).
Burke, S.K. et al., “RenaGel®, a novel calcium- and aluminum-free phosphate binder, inhibits phosphate absorption in normal volunteers,”Nephrol. Dial. Transplant.12:1640-1644 (1997).
Burke, S.K. et al., “RenaGel® Lowers Serum Phosphorous and Intact Parathyroid Hormone in Hemodialysis Patients,” Abstract. Paper presented at the meeting of theNational Kidney Foundation, San Antonio, TX (Apr. 1997).
Reiner, D. et al., “Efficacy of a nonabsorbable phosphate binder for the treatment of hyperphosphatemia in chronic hemodialysis patients,” Abstract A2636,Mineral Metabolism: Calcium/ Magnesium/Phosphorous, J. Am. Soc. Nephrol.8:566A (1997).
Chertow, G.M. et al., “A Randomized Trial of Sevelamer Hydrochloride (RenaGel) with and without Supplemental Calcium: Strategies for the Control of Hyperphosphatemia and Hyperparathyroidism in Hemodialysis Patients.” Presented at theAmerican Society of Nephrology, 30thAnnual Meeting, Nov. 2-5, 1997.
Chertow, G.M. et al., “A Long-term Study of the Effectiveness of Sevelamer Hydrochloride (RenaGel) in Hemodialysis Patients,” Abstract A2820,Mineral Metabolism: Calcium/Magnesium/Phosphorous, J. Am. Soc. Nephrol.9:552A (Sep. 1998) Program and Abstracts Issue.
Wilkes, B.M. et al., “Simultaneous lowering of serum phosphate and LDL-cholesterol by sevelamer hydrochloride (RenaGel) in dialysis patients,”Clini. Nephrol.50(6):381-386 (1998).
Chertow, G.M. et al., “Poly[allylamine Hydrochloride] (R

Affiliated with

Also associated with

Rating

Methods of treating Syndrome X with aliphatic polyamines does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Methods of treating Syndrome X with aliphatic polyamines, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods of treating Syndrome X with aliphatic polyamines will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3854680